78 related articles for article (PubMed ID: 15130315)
1. [The effect of IRESSA on H22 mouse hepatocellular carcinoma].
Zhu BD; Yuan SJ; Xu JM; Zhao QC; Li X; Li Y; Hao LH
Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(8):684-6. PubMed ID: 15130315
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.
Zhu BD; Yuan SJ; Zhao QC; Li X; Li Y; Lu QY
World J Gastroenterol; 2005 Mar; 11(9):1382-6. PubMed ID: 15761981
[TBL] [Abstract][Full Text] [Related]
3. [Inhibitory effects of iressa on hepatocellular carcinoma Hep-3B and HepG2 cell xenografts in nude mice].
Xu L; Zhang YJ; Lin XJ; Li JQ
Ai Zheng; 2006 Apr; 25(4):447-50. PubMed ID: 16613678
[TBL] [Abstract][Full Text] [Related]
4. Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis.
Guo B; Xie N; Wang Y
Bull Cancer; 2015 Mar; 102(3):204-12. PubMed ID: 25747889
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.
Chen T; Yuan SJ; Wang J; Hu W
World J Gastroenterol; 2015 Sep; 21(35):10126-36. PubMed ID: 26401077
[TBL] [Abstract][Full Text] [Related]
8. Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma.
Wang CF; Wang YQ; Huang FZ; Nie WP; Liu XY; Jiang XZ
J Int Med Res; 2013 Aug; 41(4):964-74. PubMed ID: 23867448
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of cisplatin-incorporated bio-nanocapsules as chemo-radiotherapy for human hepatocellular carcinoma.
Shin SH; Park SS; Lee KJ; Ju EJ; Park J; Ko EJ; Jung J; Kuroda S; Hong SM; Hwang JJ; Lee JS; Song SY; Jeong SY; Choi EK
Oncol Rep; 2017 Oct; 38(4):2259-2266. PubMed ID: 28849069
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
11. Immuno-modulatory and cellular antioxidant activities of κ-selenocarrageenan in combination with Epirubicin in H22 hepatoma-bearing mice.
Ling N; Zhou X; Ji Y; Li W; Ji C; Qi Z
Biomed Pharmacother; 2017 Jul; 91():132-137. PubMed ID: 28448867
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitive effect of polypeptide extract from scorpion venom on repopulation in H22 tumor cell during chemotherapy].
Wang Z; Zhang W; Jia Q; Wang Z; Zhang Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2010 Jan; 35(1):108-13. PubMed ID: 20349728
[TBL] [Abstract][Full Text] [Related]
13. [Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis].
Kitamura M; Arai K; Iwasaki Y; Takahashi T; Saitoh K; Fujii T; Shirasaka T
Gan To Kagaku Ryoho; 2000 Apr; 27(4):559-63. PubMed ID: 10790998
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect of Shaoyao Ruangan formula on mice with transplanted H22 hepatocarcinoma and its mechanism research.
Zhang HY; Jiang JW; Ni MW; Peng YS; He FG
J Cancer Res Ther; 2014 Aug; 10 Suppl 1():65-9. PubMed ID: 25207895
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor effect of recombinant immunotoxin EGF-TCS in nude mice bearing human hepatocellular carcinoma].
Yang HW; Yang HW; Li YM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1535-6. PubMed ID: 17959515
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
Ueda S; Shirabe K; Morita K; Umeda K; Kayashima H; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
Ann Surg Oncol; 2011 Apr; 18(4):1204-11. PubMed ID: 21076943
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M; Oya M
Urology; 2009 Mar; 73(3):655-60. PubMed ID: 19167032
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of Polypeptide Extract from Scorpion Venom Combined Rapamycin in Enhancing Autophagy of H22 Hepatoma Cells: an Experimental Study].
Zhao QQ; Zhang WD; Wu LC; Zhang LL; Wang ZP; Zhang YY; Wang ZX; Jia Q
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jul; 35(7):866-70. PubMed ID: 26380452
[TBL] [Abstract][Full Text] [Related]
20. [A case of hepatocellular carcinoma effectively treated by intraarterial infusion of CDDP and other agents].
Yodono H; Tarusawa K; Sasaki T; Kanehira J; Saito Y; Takahashi S; Kimura T; Nishi N; Nakamura Y; Takekawa S
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3265-8. PubMed ID: 2551253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
